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Abstract
Tramadol (TR) is a widely prescribed pain killer because of its relatively safe 
profile among opioids. Nevertheless, intoxication can occur and overdose can lead 
to fatal outcomes. Surprisingly, in some fatalities for which death is attributable 
to TR alone, postmortem blood concentration levels overlap with the therapeutic 
concentration range. These fatal cases might be explained by pharmacokinetic and 
pharmacodynamic properties of TR that are known to be both enantioselective 
and influenced by genes. Indeed pharmacogenetics (PG) is of great importance in 
this issue as it has the ability to elucidate the genetic variation contributing to drug 
absorption, distribution, metabolism, excretion, and response so that adverse drug 
reactions, toxicity, and even death can be avoided. The aim of this chapter is to 
present this issue.
Keywords: tramadol, pharmacogenetics, toxicology, post-mortem investigation, 
molecular autopsy
1. Introduction
There is large interindividual variability in drug response and toxicity, as well 
as in drug concentrations after administration of the same dosage [1]. The genetic 
makeup could be the reason of variation in drug response among individuals [2]. 
In general, genetic factors are estimated to account for 15–30% of interindividual 
differences in drug response, but for certain drugs, this can be as high as 95% [1].
The genetic variations contribute to absorption, distribution, metabolism, 
excretion, response, and adverse drug reactions, which could be explored by 
pharmacogenetics (PG). PG could also characterize differential enzyme activity 
(e.g., the cytochrome P450 system) informing appropriate drug dosage on the indi-
vidual (personalized medicine) and population levels. The advancement of genetic 
modalities will enable more accurate predictions of drug-related death determina-
tions and contribute to the growing not only in forensic toxicology context but also 
in clinical settings [2].
The main application of molecular autopsy involves investigation of drug-
related deaths by exploiting several molecular techniques, especially those of 
genetic nature [3].
The PG use as an adjunct for molecular autopsy would add to the understanding 
of potential genetic contribution to metabolism of certain drug (such as tramadol), 
thus enabling and improving the practice of antemortem drug therapy [4].
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Tramadol (TR) is a worldwide used pain killer drug. Since TR was marketed, 
it has been widely prescribed because of its relatively safe profile among opioids. 
Nevertheless, intoxication can occur and overdose can lead to fatal outcomes. 
Surprisingly, in some fatalities for which death is attributable to TR alone, postmor-
tem blood concentration levels overlap with the therapeutic concentration range 
(0.1–0.8 mg/L) [5–8]. These fatal cases might be explained by pharmacokinetic and 
pharmacodynamic properties of TR that are known to be influenced mainly by the 
CYP2D6 phenotype.
1.1 Tramadol (TR)
TR is a synthetic centrally acting analgesic drug worldwide used for the treat-
ment of moderate to severe pain [9, 10]. TR is used as a pain killer in different types 
of pain such as osteoarthritic, endodontic or dental, chronic cancer, acute renal, 
neuropathic, and postoperative pain. It is also used in case of acute myocardial 
infarction, postoperative shivering in lower abdominal surgery, Brugada syndrome, 
and morphine allergy [11].
However, several precautions should be taken before TR prescription. It should 
not be administrated below the age of 16 years, and some forms as Ultram should 
be administrated above the age of 18 years. TR should not be prescribed during 
pregnancy, in case of lactating and expecting mothers, person with epilepsy, mental 
illness or suicide attempt, heart or respiratory problems, stomach or intestinal 
blockage, liver, kidney, or metabolic disease, TR sensitivity, addiction to drug or 
alcohol, intake of some drugs as sedatives, tranquilizers, narcotics, 2 weeks intake 
of monoamine oxidase inhibitor (MAOI), methylene blue injection, antibiotics, 
antifungal, and anti-HIV medications [11].
1.2 Epidemiological data
The changes in opioid consumption have been described worldwide. In 
Europe, they were characterized by an increasing use of TR. Between 2006 and 
2015 in France, TR (alone or in combination use) were the second most commonly 
used mild opioids. There was an increased consumption of TR over the 10-year 
period (+62%) in France. In recent reports, France ranked third place for mild 
opioid consumption, with TR (alone or in combination use) being one of the most 
used substance (48%). In other European countries, TR is also the most com-
monly used mild opioids in Germany, Italy, Spain, and Denmark (98, 82, 78, and 
85%, respectively) [12].
In the same time, there is a particular concern about the rise of nonmedical use 
of analgesics, especially opioids. Much has been written about the opioid crisis in 
the USA, but a similar crisis engulfing the Middle East, North, and West Africa is 
receiving little attention [13]. Therefore, drug world report 2018 mentioned the 
critical challenge in some countries in Africa and other regions needing to grips 
with the TR crisis [14, 15].
The 2017 report of the National Survey of Substance Abuse in Egypt was 
subsequently presented to the WHO which revealed that the abuse of TR is still 
a national concern in Egypt despite it became a schedule IV controlled substance 
since 2012. This may be because of wide-scale abuse of this analgesic. In the 
2012/2013 survey, 7.6% of the general population abused drugs: of these 31.5% 
reported misuse of TR [16].
Because TR is widely used either as licit or illicit drug, FDA has only approved 
the medical use by prescription. Although TR has become a schedule IV controlled 
substance in the USA since 2014, this did not hinder legitimate access. In 2014, there 
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was a total of 43.7 million, 39.8 million, and 36.5 million TR prescriptions dispensed 
in the USA in 2016, 2017, and 2018, respectively [17].
1.3 Adverse reactions
The WHO Global Database reports of suspected adverse drug were studied to 
investigate TR. There has been a sudden increase in reports (nearly 5-fold) for TR: 
from 200 reports in 2013 to 800 in 2018 [9].
In overdose, the multiple systematic symptoms are reflecting the multimodal 
activity of TR. Acute adverse effects associated with TR are like those of other weak 
opioids. Common side effects include dizziness, nausea, constipation, and headache. 
TR overdose presented with multiple systematic symptoms ranging from cardiovas-
cular toxicity to significant neurologic toxicity including lethargy, nausea, tachycar-
dia, agitation, seizures, coma, hypertension, and respiratory depression [9].
The smallest amount of TR associated with a seizure was 200 mg occurred 
within 6 hours after ingestion. The mechanism underlying TR toxicity has been 
closely related to both opioid and MAOI activity [18]. The enhanced risk of seizure 
was attributed to the increased risk from serotoninergic toxicity due to the expected 
prolonged half-life of the ingested parent compound resulting in slower drug 
metabolism [19]. Both TR and M1 inhibit the reuptake of serotonin and noradrena-
line. Hence, the concomitant use of serotonergic drugs such as serotonin reuptake 
inhibitors and MAOIs, increase the risk of adverse events, including seizure and 
serotonin syndrome.
The parent drug of TR causes sedation (but does not impair ventilation) and 
the M1 metabolite causes both sedation and respiratory depression [now termed 
opioid-induced ventilatory impairment (OIVI)] which is responsive to naloxone 
[20]. Both monoaminergic and opioid mechanisms contribute to this effect. In a 
case series study of TR overdose, respiratory depression occurs only in severe cases 
of overdose with very high doses [9, 21].
On the other hand, other work suggested that poor metabolizers (PMs) of 
TR tend to experience more adverse effects of the drug. The results showed that 
intermediate metabolizers (IMs) were found to have a statistically higher incidence 
of adverse drug reactions (dizziness, headache, nausea, sweating, and dry mouth) 
when compared with the groups that metabolize TR faster [ultra-rapid metaboliz-
ers (UMs) and extensive metabolizers (EMs)]. Other studies found no difference 
in term of adverse events such as nausea and vomiting between patients with the 
CYP2D6 UMs, PMs, IMs, and EMs [22].
Regarding the chronicity, the main problem observed was the significant 
increase in comorbid anxiety, depressive, and obsessive-compulsive symptoms 
while there was no increase in psychotic symptoms [9].
Concerning dependence potential, the International Narcotics Control Board 
reported in 2018 widespread misconceptions regarding TR among the general 
population in North Africa and the Middle East. Some consider TR to be a mood 
enhancer that increases sexual stamina and/or boosts energy during work. 
However, mood elevation is often reported and leads to the consumption of higher 
doses of the drug, psychological or physical dependence, and increased risk of 
overdose [9, 23].
The development of physical dependence to TR is dose-related, and administra-
tions of supra-therapeutic doses lead to a similar dependence profile to morphine, 
whereas the risk of physical dependence is lower than prototypic opioids when low-
dose TR is used over an extended period. However, these are not exclusively related 
to its opioid effects and may reflect withdrawal from catecholamine and serotonin 
receptors and present as atypical sequelae [9].
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1.4 TR-related fatalities
In a report about a young Caucasian female admitted to hospital with refractory 
cardiac arrest and high levels of both TR and M1, the genetic analysis revealed the 
patient had a duplicated wild-type allele, indicative of a CYP2D6 UM phenotype. 
The event was specifically ascribed to the inhibition of noradrenaline reuptake and 
excessive blood adrenaline levels following binge-type ingestion of TR (to gain a 
“high”) that led to strong myocardial stunning [24].
In France, the number of deaths related to TR toxicity increased from 32 in 2013 
to 49 in 2017. TR was the first most commonly cause of death due to analgesics [25]. 
In Egypt, about 18% of fatalities are related to TR in the national poison center. TR 
was the second most commonly cause of death among cases attended in the poison 
center in 2012 [26].
2. Pharmacology
TR is a complex drug that is administered as a racemate with the (+)- and 
(−)-enantiomers of the parent compound and related metabolites showing various 
pharmacological effects. It is metabolized by polymorphic enzymes including CYP2D6 
and CYP3A4 to its more potent metabolites particularly O-desmethyltramadol (ODT, 
M1) as well as N,O-didesmethyltramadol (NODT, M5) [9, 10].
2.1 Pharmacokinetics
TR is marketed as the hydrochloride salt. It is available in a variety of pharma-
ceutical formulations for oral, sublingual, intranasal, rectal, intravenous, subcuta-
neous, and intramuscular administration. It is also available in combination with 
acetaminophen, immediate-release and extended-release formulations. Tablets 
and capsules are the most commonly used and easily available formulations. The 
recommended daily dose is in the range of 100–400 mg. The maximum dose should 
not exceed 400 mg/day [9].
After oral administration, TR is rapidly absorbed (with a time lag of 30 min for 
capsules). The bioavailability of TR is around 70% after single-dose administration, 
but increases to 90–100% after repeated administration as a result of the saturation 
of the hepatic first pass effect [9, 27]. TR sustained release capsules had identical 
bioavailability to TR immediate-release capsules with lower peak concentrations 
and less fluctuation in plasma concentrations [9].
The analgesic potency of TR itself is about 10% that of morphine following 
parenteral administration but more potent if administered orally because of the 
activity of M1. The production of analgesia is consistent with M1 formation, which 
commences an hour postadministration and peaks 2–3 h later [9].
The TR volume of distribution has been reported to be 2.6 and 2.9 L/kg in male 
and female subjects, respectively, following a 100 mg intravenous dose. The plasma 
binding of TR is approximately 20% [28]. TR crosses the blood-placental barrier 
and a very small amount of the drug is excreted in breast milk [29]. TR is mainly 
excreted through the kidneys, the remaining being excreted in feces [30]. About 
60% of TR dose is excreted as metabolites, meanwhile 30% is excreted in the urine 
as unchanged drug.
The elimination half-lives range of racemic TR and M1 have been reported to 
be about 5–7 h [31]. The longer elimination time of TR in case of overdose (about 
9.24 h) gives an indication about the capacity limited of TR metabolism, which is 
dependent upon the rate of metabolism by the P450 enzymatic system [9].
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2.2 Pharmacodynamics
TR acts in a multimodal fashion to bring about analgesia that involves the 
μ-opioid receptor system, the noradrenergic system, and the serotonergic system. 
TR has some affinity for the μ-opioid receptor, whereas the active hepatic metabo-
lite, M1 has high relative greater affinity for the μ-opioid receptor [32]. The affinity 
of morphine for this same receptor is approximately 10–100 times greater than 
M1 and 300 times greater than TR. TR is approximately 10-fold less potent than 
codeine. A weak agonistic TR effect was revealed at the δ-opioid receptors, and a 
weaker TR affinity was shown at κ-opioid receptors. TR acts by other mechanisms 
on the central nervous system including monoaminergic activity through weak 
noradrenaline and serotonin reuptake inhibition to prevent pain transmission [33].
TR is administered as a racemate, with the (+)- and (−)-enantiomers of the 
parent compound and their respective metabolites displaying different effects 
to achieve synergistic pain relief. The (+)-enantiomer of TR is most potent in 
serotonin reuptake inhibition, while (−)-enantiomer is a noradrenaline reuptake 
inhibitor. The (+)-enantiomer of the M1 has the highest affinity and potency up on 
the μ-opioid receptors. It also exerts most of the opioid effects. The (+)-ODT is the 
most potent stereoisomer in relieving pain as well as in causing adverse effects [10].
TR is mainly metabolized by two pathways: N- and O-demethylation (phase I 
reactions) and conjugation (phase-II reactions). There are at least 11 known metab-
olites of TR (M1–M5). The metabolites N-desmethyltramadol (M2), M3 and M4 of 
TR have negligible affinity for the human μ-opioid receptor. The O-demethylation 
of TR to M1 is catalyzed by cytochrome P450 (CYP) 2D6, whereas N-demethylation 
to M2 is catalyzed by CYP2B6 and CYP3A4 (Figure 1) [9]. M1, the active metabolite 
of TR, is metabolized through glucuronidation in the liver, mostly via UGT2B7 and 
UDP glucuronosyltransferase 1–8 (UGT1A8) [22].
2.3 Pharmacogenetics (PG)
2.3.1 Definitions
PG is the inherited variation study in relation to drug response. Its goal is to 
develop novel ways to minimize toxicity and maximize drug efficacy for the patient 
[34]. PG is an important innovation in clinical medicine as a result of progression 
of genomic science to determine the correct drug with the correct dose as a specific 
treatment with the use of genetic information [35]. Personalized medicine has 
the potential to select the most appropriate drug for certain patients, to predict 
optimal dosage for a drug, and to develop cost-effective treatments. Individualized 
response to treatment may be attributed to biological (for example age, sex, nature 
of disease), behavioral (for example smoking, drug interactions), or genetic factors 
(for example genetic variants of pharmacogenes) [34].
2.3.2 PG strengths
Personalized medicine has the finality of improving drug safety and efficacy. PG 
application in clinical practice promises more effective decision-making in relation 
to diagnostic testing, individualized drug selection, and dosing. This depends on 
the genetic variations that affect the observed differences in drug response which 
can be classified into two groups: pharmacokinetic and pharmacodynamic. The 
genes that influence the pharmacokinetic properties of a drug influence the drug 
absorption, distribution, metabolism, and excretion. The genes that affect the 
pharmacodynamic of a drug influence the mechanism of the drug’s target and how 
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it affects the body. The risk-benefit balance of a drug can be evaluated based on PG 
effects on safety, efficacy, or both. Thus, prior analysis of a patient’s genotype may 
be used to guide clinical decision because the patient may benefit from an alterna-
tive drug or reduction in dose of a standard therapy. PG has the potential to reduce 
the costs (pharmacoeconomy) associated with inappropriate drug or severe adverse 
drug reactions that require hospitalization [34].
2.3.3 PG limitations
There are several limitations of PG that invariably makes genetic-guided 
therapies unfavorable in comparison with the standard health care. One of these 
limitations is the cost of PG test as the additional expense of the genetic test has to 
be borne as an extra expenditure by the patient, or by healthcare coverage provided 
by insurance. The second common limitation is the speed of getting genetic test 
result as the speedy generation of the PG test result is as important as of the genetic 
information results itself. Imperfect understanding of genetic determinants of 
drug response is one of the common limitations which in turn affects physician and 
patient confidence to genetic test [35].
2.3.4 Opportunities for growth of PG
The landscape of PG testing is rapidly evolving. There are several factors that 
have great impacts on PG development and increase its utility such as accumula-
tions of PG data, the continuity of technological innovations with more acces-
sibility, and costs continuing to drop [35, 36]. Work has been done to suggest that 
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healthcare professionals to use pharmacogenetic tools more often. Moreover, one of 
the PG-guided clinical trial principle is to improve and accelerate drug development 
by correlating genetic patient profile with treatment outcomes in early clinical trial 
phase, and subsequently extending Phase III only to individuals having the genetic 
predispositions linked to the safe and effective use of the tested drugs [35].
2.3.5 Uses of PG
PG can enhance patient care by applying treatments tailored to genetic make-
up and decreasing the risk of severe adverse effects. In 2019, there are 132 PG 
dosing guidelines for 99 drugs and PG information is included in 309 drug labels. 
Recently, the genotyping has become more accessible. Next generation sequencing 
is a cost-effective choice to genotype samples at many PG loci simultaneously [37], 
and guidelines are available from organizations such as Clinical Pharmacogenetics 
Implementation Consortium and Dutch Pharmacogenetics Working Group [36].
As mentioned earlier, the major P450 enzyme activities involved in drug 
metabolism are influenced by genetic variations. Thus, it is not surprising that 
the currently available examples of the beneficial use of PG in the interpretation 
of forensic toxicology data predominantly concern drugs that are extensively 
metabolized by P450s. Many cases exhibited severe intoxication or even death 
can be attributed to genetic variations in drug-metabolizing enzymes leading 
to toxic concentrations of either the parent drug or metabolite(s) in the body. 
Therapeutic opioids (as codeine, TR, oxycodone, hydrocodone, ethylmorphine, and 
methadone), selective serotonin reuptake inhibitors (as fluoxetine, fluvoxamine, 
paroxetine, sertraline, and citalopram), and tricyclic antidepressants are com-
monly implicated in severe adverse effects, as well as drug-related deaths because of 
certain genetic polymorphisms which affect the drug metabolism [38].
2.3.6 PG and TR
The CYP2D6 enzyme is accountable for the formation of M1 (Figure 1). 
Individuals may be classified as PM, IM, EM, or UM according to the metabolic 
activity of the CYP2D6 enzyme, determined by either phenotyping or predicted 
from genotyping (Table 1) [10]. CYP2D6 genotype data are commonly arranged 
into star (*) alleles. The intermediate (extensive/normal commonly divided into 
fast [NM-F] and slow [NM-S] subgroups) [39]. Individuals with two functional 
CYP2D6 alleles or one functional and one decreased functional allele were classified 
as EM. Individuals with one nonfunctional allele and one functional or decreased 
functional allele are identified as IM [10]. A carrier of two reduced function is also 
considered IM [22]. Individuals with two nonfunctional alleles as PMs. UMs were 
defined as individuals with CYP2D6 multiplications, resulting in at least three 
functional CYP2D6 alleles [10].
Different pharmacological effects can therefore be expected depending on an 
individual’s CYP2D6 phenotype. Both pharmacological properties (opioidergic 
and monoaminergic) of the drug may also be modified because of modulation of 
P450 enzymatic activity by genetic polymorphisms and/or drug interactions. The 
opioidergic properties will be very clear in UM, meanwhile the monoaminergic 
antidepressant activity will be very clear in PM [40].
The PM, in comparison to EM, have an increased exposure to (+)- and (−)-TR 
combined with a reduced formation of especially (+)-ODT but also of (−)-ODT. UM, 
on the contrary, are expected to form higher amounts of (+)-ODT than EM and to be 
more prone to opioid- related adverse effects. Comparisons between EM and UM are, 
however, sparse in scientific literature [10]. PMs are experiencing better pain relief 
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than IMs who may experience insufficient relief. UMs are being more likely to experi-
ence adverse effects from TR because of the more rapid release of M1 [9].
Apart from M1, there are two additional primary TR metabolites, M2 and M5. 
M2 is an inactive metabolite which its formation is mediated by presence of two 
enzymes (CYP2B6 and CYP3A4), while M5 has some opioid effects and its meta-
bolic route is less assured. However, all three enzymes (CYP2D6, CYP2B6, and 
CYP3A4) are involved in TR metabolism (Figure 1) [10].
The CYP2B6 gene is highly polymorphic as well as CYP2D6, but the relevance of 
CYP2B6 polymorphisms in TR has been less studied. Many CYP3A4 polymorphisms 
have been identified, although it is not well associated with the phenotypical vari-
ability. The CYP3A4*22 allele is associated with reduction of the enzymatic activity. 
Recent study tried to explain if the interindividual differences in enantioselective 
metabolic profiles could be explained by CYP2D6, CYP2B6, and/or CYP3A4 geno-
type. This item hypothesized that interindividual differences are better explained 
by the combined genotype of all three enzymes involved in the metabolism of the 
drug, rather than by CYP2D6 itself [10].
Rudaz et al. showed that enantiomer ratios of all four compounds in urine 
changed over time in one individual administered 100 mg TR [41]. The largest 
increase in enantiomer ratio was observed for M2 in CYP2D6 EM and IM, rising 
from about two to almost seven during 24 h following drug intake. Homozygosity 
of CYP2B6*5 and *6 indicated a reduced enzyme function, although further 
studies are required to confirm it. The significance of CYP2B6 polymorphisms 
in TR pharmacokinetics has not been carefully investigated. The same study 
concluded that consideration for the time is important when you assess enantio-
mer ratios as it might possibly be used to distinguish a recent TR intake from a 
past one [10].
Of additional relevance is the significant interethnic differences in CYP2D6 allele 
frequencies demonstrated across many countries [9]. For example, the CYP2D6*1 
seems to be the most prevalent in studied groups from Egyptians. In contrast, 
CYP2D6*4, CYP2D6*10 and CYP2D6*DUP showed minor occurrence [42].
Chronic treatment with TR induced hepatotoxicity in all patients with dupli-
cated or normal function (CYP2D6*DUP or *1) allele in UMs and EMs displayed 
higher blood levels of M1, but in none of the patients with impaired or reduced 
















IM 1 2/1 1/ 1
PM 0 0 2
Examples *1 *9, *10, *17(Z) *3, *4, *5, *6, *14
UM, ultra-rapid metabolizer; EM, extensive metabolizer; IM, intermediate metabolizer; PM, poor metabolizer.
Table 1. 
CYP2D6 phenotypes in relation to their genotypes.
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3. Detection of TR
3.1 Techniques
Toxicological analysis of TR is based on chemical spot tests, immunoassays, 
mass spectrometry, and chromatography.
• Preliminary urine multidrug screen tests as well as automated immunoassay 
systems which are commonly used with a 0.3 mg/L cut-off value [43].
• Gas chromatography-mass spectrometry (GC-MS) can be used to analyze 
blood samples for detection of TR and its metabolites. Blood concentrations 
are ranging from 0.03 to 22.59 mg/L, from 0.02 to 1.84 mg/L and from 0.01 to 
2.08 mg/L for TR, M1, and M2, respectively [9, 44].
• Liquid chromatography-tandem mass spectrometry (LC-MS/MS) method 
was developed for the quantitation of TR and its main metabolites in hair. 
The Lower detected Limits were in the range 0.010–0.030 ng/mg hair. The 
TR, M1, and M2 concentrations were markedly lower in the nonabuse cases 
(3.3–20.1 ng/mg, 0.3–1.9 ng/mg, 0.5–4.3 ng/mg, respectively) compared 
to the abuse cases (63.4–107 ng/mg, 3.8–6.3 ng/mg, 24.9–45.7 ng/mg hair, 
respectively); also the M2/M1 ratio differed significantly. Hair has become an 
important biomarker owing to the possibility of detecting target analytes for 
periods >1 month [45].
• Liquid chromatography coupled to fluorescence detection was also used for 
TR and its main metabolites M1 and M2 and M5 simultaneous determina-
tions in human plasma, oral fluid, and urine. The lower limit of detection was 
2.5 ng/mL for all compounds. The assay was applied to assess the pharmaco-
kinetics of TR and its main metabolites following administration of a single 
oral dose (100 mg) TR to healthy volunteers [46]. Maltodextrin-modified 
capillary electrophoresis method was reported to detect the stereoisomers of 
TR for a single-run chiral separation of TR with detection limit of 2 mg/L. 
This method was approved to measure the concentration of drug in plasma 
samples, urine, and tablets [47].
• HPLC (linear dual column-MS/MS) was successfully used on oral fluid for the 
simultaneous detection of TR and its metabolite (M1, M2, and M5) [33].
3.2 Interpretations of toxicological and genetic analyses
Different studies tried to correlate concentrations of TR and its metabolites with 
different genotyping of CYP2D6. The best correlation was obtained for M2/M1 ratio 
and PM. The M2/M1 ratio in PM is almost above 7 [48].
Levo et al. calculated the TR/M1 and TR/M2. When the number of functional 
alleles increased, the median TR/M1 decreased. They also showed that median TR/M2 
also correlated with the number of functional alleles, but in the reverse direction, as 
can be expected based on the complementary nature of two pathways [49].
The literature reported the value of M1/M2 ratio in case of massive TR intoxica-
tion. A quick death has been expected in case of M1/M2 is more than 1 [50].
The metabolic profiles of CYP2D6 PM showed large area under curve (AUCs) 
of the M2 enantiomers with low corresponding values of the M1 and M5 enantio-
mers. The (+)-enantiomers of M1 and M5 were affected to a larger extent than the 
Forensic Analysis - Scientific and Medical Techniques and Evidence under the Microscope
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(−)-enantiomers. The observed reduced levels of the M5 enantiomers were expected. 
M5 is formed from both M1 and M2. Since PMs only form low amounts of M1 due to 
the abolished (canceled) function of CYP2D6, the amounts of the M2 enantiomers 
will accumulate. Another metabolic profile of CYP2D6 IM showed the AUCs of both 
the M2 and M5 enantiomers exceeded the ones of the M1 enantiomers [10].
The general hypothesis in literature regarding adverse effects following TR 
administration is that the frequency and intensity is related to the concentrations of 
(+)-M1. The higher the concentration of (+)-M1, the higher the risk of side effects 
and toxicity. In Haage et al. study, the individual experiencing most drug reaction 
symptoms (both fainting and vomiting during the experimental day) was the one 
with the second lowest maximal concentration and AUC of (+)-M1 in the 100 mg 
dosage group [10].
A recent work reported that the TR/M1 ratio may not accurately reflect the 
rate of TR O-demethylation in clinical patients. This study accounted that due to 
(i) postmortem redistribution (PMR) phenomenon, and (ii) various interval and/
or time between TR administration and death. In addition, TR is metabolized by 
multiple enzymes (e.g., TR and/or its metabolites are metabolized by CYP2D6, 
CYP3A4, CYP2B6, UGT1A8, or ABCC2) (Figure 1) and may be metabolized at 
different rates based on body size, liver function, chronicity of TR, general opioid, 
and/or other drug use [39]. Surprisingly, the first abovementioned cause is not 
accurate as PMR is not a problem in case of interpretation of fatalities related to TR. 
Indeed, many studies revealed that cardiac-to-femoral blood ratios obtained for TR 
and M1 are close to 1 [51–54].
It is suggested that the monogenic model likely introduces error, particularly for 
samples at the extremes of CYP2D6 activity; a prediction using multiple genes may 
reduce these discrepancies although this comparison has not been performed. The 
forensic community has not yet leveraged the power of machine learning for such 
studies. However, the forensic DNA community has begun developing methods of 
individualizing humans [39].
4. Conclusion
This chapter about PG and TR highlights important related issues including 
pharmacological and genetic aspects of TR. It clarified the interindividual variabil-
ity in response and toxicity to TR in order to support the use of genetic screening 
to predict individual responses to pain medications and the risk of adverse events. 
This in turn will encourage the use of PG as part of clinical practice for TR. Finally, 
novel machine learning approaches using multigenic model can comprehensively 
analyze genotype-phenotype relationships that hold significant promise for appli-
cation to predict response to TR, which may contribute to the relatively high rate of 
TR-related fatalities.
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Appendices and nomenclature
EMs or NMs Extensive or normal metabolizers
GC-MS Gas chromatography-mass spectrometry
IMs Intermediate metabolizers
LC-MS/MS Liquid chromatography-tandem mass spectrometry
M1 or ODT O-desmethyltramadol
M2 N-desmethyltramadol
M5 or NODT N,O-didesmethyltramadol
MAOI Monoamino oxidase inhibitors
NM-F Fast normal metabolizers
NM-S Slow normal metabolizers
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